Compared to small drug molecules (EGFR-TKIs) and monoclonal antibodies (PD-1/PD-L1 checkpoint inhibitors), the two most important types of drug molecules in NSCLC therapy, siRNA has several distinct advantages. This evidence concerns the gene EGFR and non-small cell lung carcinoma.